2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
73
Colonic Neoplasms
14
Rectal Neoplasms
13
Neoplasm Metastasis
12
Stomach Neoplasms
8
Pancreatic Neoplasms
5
Advanced Solid Tumors
5
Neoplasms
4
Colorectal Cancer Metastatic
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Gallbladder Neoplasms
3
Cholangiocarcinoma
3
Carcinoma
3
Adenocarcinoma
3
Neutropenia
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Biliary Tract Neoplasms
2
Bile Duct Neoplasms
2
Advanced Solid Tumors (Excluding Breast Cancer)
2
Advanced Colorectal Cancer
2
Adenocarcinoma Of Esophagus
2
mCRC
1
Urologic Diseases
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Spinocerebellar Degenerations
1
Solid Tumor Cancer
1
Solid Tumor
1
Interventions
pembrolizumab
5
Oxaliplatin
3
Nivolumab
3
sintilimab
2
Leucovorin
2
Immune Checkpoint Inhibitors
2
Fluorouracil
2
Capecitabine
2
Bevacizumab
2
vicriviroc
1
trifluridine tipiracil drug combination
1
spartalizumab
1
relatlimab
1
regorafenib
1
epacadostat
1
dabrafenib
1
copanlisib
1
binimetinib
1
atezolizumab
1
Tiragolumab
1
Irinotecan
1
Fulvestrant
1
E7046
1
Cetuximab
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Spinocerebellar Degenerations
×
trifluridine tipiracil drug combination
×
Clear all
NCT05328908
2025-08-13
RELATIVITY-123
Bristol-Myers Squibb
Phase 3
Terminated
770 enrolled